Detection of Genetic Markers of Lung Cancer
Detection of Genetic Markers of Lung Cancer Initiation and Progression
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 5 years
- Procedures mentioned: X-rays
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "These patients will then be followed for five years to determine tumor recurrence."
- "This information could then be applied to clinical situations, for example, to determine the frequency of clinical follow-up by chest x-ray, screening bronchoscopy, or sputum cytology."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy * Written informed consent. * To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass Exclusion Criteria: None
Study sites (1)
PA
- Hillman Cancer Center · Pittsburgh, PA 15232Julie A Ward, BSN · Study contact · 412-647-8583 · wardj@upmc.eduJames D. Luketich, MD · Sub-investigatorNeil A. Christie, MD · Sub-investigatorMatthew Schuchert, MD · Sub-investigatorMore trials in Pittsburgh